| Cytokines in clinical cancer immunotherapy P Berraondo, MF Sanmamed, MC Ochoa, I Etxeberria, MA Aznar, ... British journal of cancer 120 (1), 6-15, 2019 | 1003 | 2019 |
| Intratumoural administration and tumour tissue targeting of cancer immunotherapies I Melero, E Castanon, M Alvarez, S Champiat, A Marabelle Nature Reviews Clinical Oncology 18 (9), 558-576, 2021 | 272 | 2021 |
| Paradigms on immunotherapy combinations with chemotherapy D Salas-Benito, JL Pérez-Gracia, M Ponz-Sarvisé, ME Rodriguez-Ruiz, ... Cancer discovery 11 (6), 1353-1367, 2021 | 232 | 2021 |
| Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective … A Carmona-Bayonas, P Jiménez-Fonseca, J Virizuela Echaburu, ... Journal of Clinical Oncology 33 (5), 465-471, 2015 | 182 | 2015 |
| Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score) F Bigot, E Castanon, C Baldini, A Hollebecque, A Carmona, ... European Journal of Cancer 84, 212-218, 2017 | 170 | 2017 |
| Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer I Baraibar, I Melero, M Ponz-Sarvise, E Castanon Drug safety 42, 281-294, 2019 | 93 | 2019 |
| Chronic opioid therapy in long-term cancer survivors A Carmona-Bayonas, P Jiménez-Fonseca, E Castañón, ... Clinical and Translational Oncology 19, 236-250, 2017 | 72 | 2017 |
| Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study C Font, A Carmona-Bayonas, C Beato, Ò Reig, A Sáez, ... European Respiratory Journal 49 (1), 2017 | 66 | 2017 |
| Intratumoral nanoplexed poly I: C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors I Márquez-Rodas, F Longo, ME Rodriguez-Ruiz, A Calles, S Ponce, ... Science Translational Medicine 12 (565), eabb0391, 2020 | 65 | 2020 |
| A Trial of Lopinavir-Ritonavir in Covid-19. P Dalerba, B Levin, JL Thompson N Engl J Med 382 (21), 2020 | 65 | 2020 |
| LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours Z Lwin, C Gomez-Roca, E Saada-Bouzid, E Yanez, FL Muñoz, SA Im, ... Annals of Oncology 31, S1170, 2020 | 63 | 2020 |
| LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. C Gomez-Roca, E Yanez, SA Im, E Castanon Alvarez, H Senellart, ... Journal of Clinical Oncology 39 (3_suppl), 94-94, 2021 | 60 | 2021 |
| Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients L Ceniceros, J Aristu, E Castañón, C Rolfo, J Legaspi, A Olarte, ... Clinical and Translational Oncology 18, 259-268, 2016 | 56 | 2016 |
| Novel strategies exploiting interleukin-12 in cancer immunotherapy A Cirella, C Luri-Rey, CA Di Trani, A Teijeira, I Olivera, E Bolaños, ... Pharmacology & therapeutics 239, 108189, 2022 | 55 | 2022 |
| Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or … L Carter European journal of cancer, 2016 | 51 | 2016 |
| Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index A Carmona-Bayonas, P Jiménez-Fonseca, C Font, F Fenoy, R Otero, ... British journal of cancer 116 (8), 994-1001, 2017 | 49 | 2017 |
| Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy E Castañon, J Bosch-Barrera, I López, V Collado, M Moreno, ... Journal of translational medicine 11, 1-8, 2013 | 47 | 2013 |
| A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis J Rodriguez, E Castañón, JL Perez-Gracia, I Rodriguez, A Viudez, ... Journal for Immunotherapy of Cancer 6, 1-7, 2018 | 45 | 2018 |
| cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance N Van Der Steen, P Pauwels, I Gil-Bazo, E Castañon, L Raez, ... Cancers 7 (2), 556-573, 2015 | 41 | 2015 |
| The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche E Castañón, A Soltermann, I López, M Román, M Ecay, M Collantes, ... Cancer letters 402, 43-51, 2017 | 37 | 2017 |
